Nothing Special   »   [go: up one dir, main page]

CL2016001753A1 - Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer - Google Patents

Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer

Info

Publication number
CL2016001753A1
CL2016001753A1 CL2016001753A CL2016001753A CL2016001753A1 CL 2016001753 A1 CL2016001753 A1 CL 2016001753A1 CL 2016001753 A CL2016001753 A CL 2016001753A CL 2016001753 A CL2016001753 A CL 2016001753A CL 2016001753 A1 CL2016001753 A1 CL 2016001753A1
Authority
CL
Chile
Prior art keywords
antibody
pharmaceutical compositions
cancer treatment
netrin
humanized monoclonal
Prior art date
Application number
CL2016001753A
Other languages
English (en)
Inventor
Jean-Guy Delcros
Yann Dean
Original Assignee
Netris Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netris Pharma filed Critical Netris Pharma
Publication of CL2016001753A1 publication Critical patent/CL2016001753A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

ANTICUERPO MONOCLONAL HUMANIZADO QUE SE UNE ESPECÍFICAMENTE A NETRINA-1, COMPOSICIONES FARMACÉUTICAS Y USOS DEL ANTICUERPO PARA EL TRATAMIENTO DEL CÁNCER
CL2016001753A 2014-01-10 2016-07-08 Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer CL2016001753A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14305034.2A EP2893939A1 (en) 2014-01-10 2014-01-10 Anti-netrin-1 antibody

Publications (1)

Publication Number Publication Date
CL2016001753A1 true CL2016001753A1 (es) 2017-05-19

Family

ID=49958401

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001753A CL2016001753A1 (es) 2014-01-10 2016-07-08 Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer

Country Status (28)

Country Link
US (2) US10494427B2 (es)
EP (2) EP2893939A1 (es)
JP (1) JP6586095B2 (es)
KR (1) KR102360967B1 (es)
CN (1) CN105979966B (es)
AR (1) AR099068A1 (es)
AU (1) AU2015205575B2 (es)
BR (1) BR112016015811B1 (es)
CA (1) CA2936308C (es)
CL (1) CL2016001753A1 (es)
DK (1) DK3092003T3 (es)
EA (1) EA034676B1 (es)
ES (1) ES2770620T3 (es)
HR (1) HRP20192313T1 (es)
HU (1) HUE048088T2 (es)
IL (1) IL246603B (es)
LT (1) LT3092003T (es)
MX (1) MX2016009029A (es)
NZ (1) NZ721975A (es)
PH (1) PH12016501339A1 (es)
PL (1) PL3092003T3 (es)
PT (1) PT3092003T (es)
RS (1) RS59818B1 (es)
SG (1) SG11201605562VA (es)
SI (1) SI3092003T1 (es)
TW (1) TWI699211B (es)
WO (1) WO2015104360A1 (es)
ZA (1) ZA201604640B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2893939A1 (en) * 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
TW201720459A (zh) 2015-11-02 2017-06-16 妮翠斯製藥公司 Ntn1中和劑與抑制後生控制之藥物之組合治療
CN110291105B (zh) * 2017-01-05 2024-03-01 奈特里斯药物公司 导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗
EP4037712A4 (en) * 2019-10-04 2023-11-01 Albert Einstein College of Medicine KIR3DL3 AS AN INHIBITOR RECEPTOR OF THE IMMUNE SYSTEM AND ITS USES
EP4377341A1 (en) 2021-07-27 2024-06-05 Netris Pharma Netrin-1 detection, companion test and therapy based on radiations
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
WO2023186968A1 (en) 2022-03-29 2023-10-05 Netris Pharma Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
WO2024180085A1 (en) 2023-02-27 2024-09-06 Netris Pharma Anti-netrin-1 monoclonal antibody for treating endometriosis and associated pains

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
DK0970126T3 (da) 1997-04-14 2001-08-13 Micromet Ag Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU2001293870A1 (en) 2000-10-16 2002-04-29 Bayer Aktiengesellschaft Regulation of human netrin binding membrane receptor unc5h-1
WO2005074556A2 (en) 2004-01-30 2005-08-18 The General Hospital Corporation Netrin compositions and methods of use thereof
CA2573720A1 (en) 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
JP5089397B2 (ja) 2004-11-22 2012-12-05 サントル ナシオナル ドゥ ラ ルシェルシェ シアンティフィク 変異ネトリン４、その断片及びこれらの薬剤としての使用
FR2878165A1 (fr) * 2004-11-22 2006-05-26 Centre Nat Rech Scient Nouvelles utilisations des netrines
US20060153840A1 (en) 2005-01-12 2006-07-13 Anne Eichmann Methods for preventing or treating a condition or a disease associated with angiogenesis
SI1989546T1 (sl) * 2006-02-28 2016-12-30 Centre National De La Recherche Scientifique (Cnrs) Presejanje za spojine proti raku z uporabo aktivnosti netrina-1
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2009141440A1 (en) 2008-05-21 2009-11-26 Centre National De La Recherche Scientifique (Cnrs) Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma
JP5147062B2 (ja) 2008-07-17 2013-02-20 Ｎｅｃトーキン株式会社 巻線部品
AR074369A1 (es) 2008-11-20 2011-01-12 Genentech Inc Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
EP2208738A1 (en) * 2009-01-09 2010-07-21 Centre National pour la Recherche Scientifique (CNRS) Method for the selection of endothelial cells death inducers via netrin-1 and its applications
US8052960B2 (en) * 2009-01-20 2011-11-08 The Penn State Research Foundation Netrin-1 as a biomarker of injury and disease
US20130336972A1 (en) 2010-08-26 2013-12-19 Christian Klein Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc
EP2708231A1 (en) * 2012-09-12 2014-03-19 Netris Pharma Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
EP2708241A1 (en) * 2012-09-12 2014-03-19 Netris Pharma Recombinant Fc-fusion protein of the two Immunoglobulin domains of UNC5
AU2014295052B2 (en) * 2013-07-23 2018-08-30 Novaliq Gmbh Stabilized antibody compositions
EP2893939A1 (en) * 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody

Also Published As

Publication number Publication date
PT3092003T (pt) 2020-02-03
EP3092003B1 (en) 2019-11-06
IL246603A0 (en) 2016-08-31
US11648309B2 (en) 2023-05-16
DK3092003T3 (da) 2020-01-20
EP3092003A1 (en) 2016-11-16
SI3092003T1 (sl) 2020-03-31
WO2015104360A1 (en) 2015-07-16
HUE048088T2 (hu) 2020-05-28
US20180072800A1 (en) 2018-03-15
AU2015205575B2 (en) 2017-09-21
TWI699211B (zh) 2020-07-21
PL3092003T3 (pl) 2020-05-18
EP2893939A1 (en) 2015-07-15
US20200079842A1 (en) 2020-03-12
JP2017505607A (ja) 2017-02-23
PH12016501339B1 (en) 2016-08-15
US10494427B2 (en) 2019-12-03
KR20160106074A (ko) 2016-09-09
TW201605476A (zh) 2016-02-16
CA2936308A1 (en) 2015-07-16
RS59818B1 (sr) 2020-02-28
JP6586095B2 (ja) 2019-10-02
EA201691212A1 (ru) 2016-12-30
EA034676B1 (ru) 2020-03-05
CN105979966B (zh) 2021-06-08
AR099068A1 (es) 2016-06-29
CA2936308C (en) 2023-02-28
BR112016015811B1 (pt) 2023-09-26
SG11201605562VA (en) 2016-08-30
HRP20192313T1 (hr) 2020-03-20
BR112016015811A2 (pt) 2018-03-27
KR102360967B1 (ko) 2022-02-08
ES2770620T3 (es) 2020-07-02
ZA201604640B (en) 2019-03-27
MX2016009029A (es) 2016-09-09
NZ721975A (en) 2022-07-29
IL246603B (en) 2020-01-30
AU2015205575A1 (en) 2016-07-21
LT3092003T (lt) 2020-01-27
CN105979966A (zh) 2016-09-28
PH12016501339A1 (en) 2016-08-15

Similar Documents

Publication Publication Date Title
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
HK1245134A1 (zh) 用抗lap單克隆抗體治療癌症
CU20150128A7 (es) Conjugados fármaco-anticuerpo
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
UY35399A (es) Conjugados de fármacos con anticuerpos
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
DK3119808T3 (da) Antistofsammensætninger til tumorbehandling
CL2016002156A1 (es) Anticuerpo que une erbb-2 y erbb-3
GEP20217331B (en) Anti-tigit antibodies
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
PE20180315A1 (es) Anticuerpos para cd40
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
CO2017003005A2 (es) Anticuerpos anti-mfi2
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
NZ771169A (en) Antibodies that bind human c6 and uses thereof